Thomas R. Coolidge
23Patents
15h-index
15Co-inventors
78Inventor score
Filing activity: Jun 30, 1989 → Nov 12, 2010
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6284725A | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue | Human Necessities | 141 | Expired |
| US6998387B1 | Human appetite control by glucagon-like peptide receptor binding compounds | Human Necessities | 139 | Expired |
| US6706689B2 | Treatment of acute coronary syndrome with GLP-1 | Human Necessities | 94 | Expired |
| US6894024B2 | Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide | Human Necessities | 61 | Expired |
| US6429197B1 | Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain | Human Necessities | 56 | Expired |
| US6982248B2 | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue | Human Necessities | 54 | Expired |
| US7056887B2 | Treatment of acute coronary syndrome with GLP-1 | Human Necessities | 44 | Expired |
| US7265087B1 | Exendin improves β-cell response in subjects with impaired glucose tolerance | Human Necessities | 37 | Expired |
| US5221736A | Sequential peptide and oligonucleotide syntheses using immunoaffinity techniques | Emerging Cross-Sectional Technologies | 36 | Expired |
| US5595887A | Purification directed cloning of peptides using carbonic anhydrase as the affinity binding segment | Chemistry; Metallurgy | 33 | Expired |
| US7259136B2 | Compositions and methods for treating peripheral vascular disease | Human Necessities | 29 | Expired |
| US5635371A | Chemical method for selective modification of the N- and/or C-terminal amino acid .alpha.-carbon reactive group of a recombinant polypeptide or a portion thereof | Emerging Cross-Sectional Technologies | 22 | Expired |
| US5464759A | Sequential oligonucleotide syntheses using immunoaffinity techniques | Emerging Cross-Sectional Technologies | 22 | Expired |
| US7888314B2 | Compositions and methods for treating peripheral vascular disease | Human Necessities | 21 | Expired |
| USRE41288E1 | Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain | General | 16 | Expired |
| US7981861B2 | Method of performing angioplasty with a GLP-1 molecule | Human Necessities | 15 | Active |
| US8551947B2 | Treatment of hibernating myocardium with an exendin peptide | Human Necessities | 15 | Active |
| US5700775A | Method and treatment composition for decreasing patient time in catabolic state after traumatic injury | Human Necessities | 12 | Expired |
| US5279954A | Exopeptidase catalyzed site-specific bonding of supports, labels and bioactive agents to proteins | Emerging Cross-Sectional Technologies | 11 | Expired |
| US5234820A | Exopeptidase catalyzed site-specific bonding of supports, labels and bioactive agents to proteins | Emerging Cross-Sectional Technologies | 7 | Expired |
| US5656456A | Chemical method for selective modification of the N- and/or C-terminal amino acid .alpha.-carbon reactive group of a recombinant polypeptide or a portion thereof | Emerging Cross-Sectional Technologies | 7 | Expired |
| US6127150A | Purification cloning of peptides | Chemistry; Metallurgy | 3 | Expired |
| US5741686A | Exopeptidase catalyzed site-specific bonding of supports, labels and bioactive agents to proteins | Emerging Cross-Sectional Technologies | 2 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.